Enhanced Recovery After Surgery Exercise Improve Perioperative Frailty (EEIPF)

Enhanced Recovery After Surgery Exercise Improve Perioperative Frailty of Patients Undergoing Elective Surgery:a Randomized Controlled Clinical Trial

A randomized, controlled, clinical trial on the efficacy of ERAS exercise improve perioperative frailty in patients undergoing elective laparoscopic colorectal surgery

Objective to evaluate the efficacy of ERAS exercise improve perioperative frailty in patients undergoing elective laparoscopic colorectal surgery

Participants: Patients undergoing elective laparoscopic colorectal surgery over 18 years old.

The research intervention was ERAS exercise

The study design was a randomized, parallel controlled trial

ERAS exercise in perioperative period as the experimental group. No ERAS exercise group was the control group.

The sample size was estimated according to the main efficacy index ( the attenuation of frailty after 7 days surgery) of this study. It was assumed that the attenuation of frailty in the ERAS exercise group was better than that of the control group. The parameters were set as test level (alpha) of 0.050 using a two-sided two-sample unequal-variance t-test, β = 0.9, according to the results of previous clinical trials and combined with literature, the population mean difference was 0.6 with standard deviations of 0.8 for the experimental group and 0.8 for the control group. the experimental group: the control group was 1:1, 39 cases in each group, considering the 20% shedding rate, 49 cases in the experimental group and 49 cases in the control group were selected.

  1. The experimental group The patients take ERAS exercise from hospitalization to 30 days after operation.
  2. The control group The patients do not take ERAS exercise in perioperative period.

Efficacy evaluation

  1. The primary endpoint of the study was the attenuation of frailty via Frailty Phenotype (FP) between before surgery and 7days, 30 days after surgery.
  2. Secondary endpoints included the 6-minute walk test (6MWT),nutritional risk screening (NRS2002), anxious and depressive states, activities of daily living (ADL),postoperative complications and mortality,short-term recovery quality,postoperative pain.

Study Overview

Status

Enrolling by invitation

Conditions

Study Type

Interventional

Enrollment (Anticipated)

98

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Chongqing
      • Chongqing, Chongqing, China, 400016
        • The First Affiliated Hospital of Chongqing Medical University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 100 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients receiving elective laparoscopic colorectal surgery.
  • 18≤age≤100 years old, no gender limit;
  • The ASA score is between I and Ⅲ;
  • Clearly understand and voluntarily participate in the study, and sign an informed consent form.

Exclusion Criteria:

  • Emergency surgery;
  • Those with a history of cognitive dysfunction;
  • Those with a history of neuromuscular diseases,;
  • American Society of Anesthesiologists class ⩾IV;
  • Those with a history of spontaneous pneumothorax, coagulation dysfunction,
  • Acute and systemic infectious diseases, moderate or higher fever;
  • Pregnant women;
  • History of drug abuse;
  • Those who judged by the physician in charge to be unsuitable for ERAS-exercise;
  • Other severe cardio-pulmonary diseases that would affect the 6MWD
  • Those failure to obtain informed consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ERAS exercise in perioperative period.
The patients take ERAS exercise from hospitalization to 30 days after operation.
Take ERAS exercise twice a day from hospitalization to 30 days after surgery
Sham Comparator: No ERAS exercise in perioperative period.
The patients do not take ERAS exercise in perioperative period.
Don't take ERAS exercise in perioperative period

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Frailty status
Time Frame: Change from Baseline Fried's Frailty Phenotype scores at 30 days postoperatively
Frailty status (i.e. robust, prefrail or frail) measured using the Fried's Frailty Phenotype (FP) scores. Frailty scores from 0 to 5 (i.e., 1 point for each component; 0 = best to 5 = worst) and represent robust (0), pre-frail (1-2), and frail (3-5) health status.
Change from Baseline Fried's Frailty Phenotype scores at 30 days postoperatively

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in gait speed
Time Frame: baseline, at 30 days postoperatively
This outcome will be measured using the 5-meter walk test.
baseline, at 30 days postoperatively
Handgrip strength
Time Frame: baseline, at 30 days postoperatively
Handgrip strength will be measured using a dynamometer.
baseline, at 30 days postoperatively
Perioperative functional capacity
Time Frame: baseline, at 30 days postoperatively
The 6-minute walk distance (6MWD) test is a non-encouraged test performed in a 30 meters long flat corridor, where the participant is instructed to walk as far as possible, back and forth around two cones, with the permission to slow down, rest, or stop if needed. Ambulation was assessed via the 6MWD test following standardized procedures by measuring the 6MWD in meters. Participants were not permitted to use assistive devices (walker, long leg braces, or short leg braces) during the 6MWD test. Participants with confirmed loss of ambulation at a particular visit were assigned a 6MWD result of 0.
baseline, at 30 days postoperatively
Patient mood state
Time Frame: baseline and 7th day postoperatively
This outcome will be assessed using Hospital Anxiety and Depression Scale (HADS) questionnaire. The HADS is a fourteen item scale. Seven of the items relate to anxiety and seven relate to depression. The anxiety and depression subscales each range from 0 to 21, with higher scores indicating higher anxiety/depression complains. Patients were defined as having anxiety or depression or both if the score was 8 or more in the corresponding subscale.
baseline and 7th day postoperatively
Nutritional status
Time Frame: baseline, at 30 days postoperatively
This outcome will be assessed using Nutritional Risk Screening 2002 (NRS-2002): The patients were classified as being nutritionally risk (NRS+): total score ≥ 3 or nutritionally risk-free (NRS-): total score < 3 according to NRS 2002 results.
baseline, at 30 days postoperatively
Short-term recovery quality
Time Frame: baseline, 1st, 2nd, 3rd and 7th day postoperatively
This outcome will be measured using 9-item quality of recovery(QoR-9) score.The QoR-9 is a 9-item score evaluating both physical and mental well-being by assessing five dimensions: emotional state, physical comfort, psychological support, physical independence and pain. Each of the 9 items are scored by the patient from 0 (worst score) to 2 (best score), giving a lowest possible score of 0 (worst outcome), and a highest possible score of 18 (best outcome).
baseline, 1st, 2nd, 3rd and 7th day postoperatively
Postoperative Complications
Time Frame: 30 days postoperatively
Postoperative Complications evaluated by Clavien- Dindo Score.Nine domains are evaluated: Pulmonary, infectious, renal, gastrointestinal, cardiovascular, neurological, wound, haematological and pain. Each domain is graded between grade I and V (death of a patient).
30 days postoperatively
Postoperative 30-day mortality
Time Frame: 30 days postoperatively
Rate of Mortality among study patients
30 days postoperatively
Highest VAS Pain Score at Rest
Time Frame: baseline, 1st, 2nd, 3rd and 7th day postoperatively
Post-operative pain scores at rest, as assessed by Visual Analog Pain Scale (VAS) will be the primary outcome measured. Postoperative pain at rest will be defined as the highest VAS pain score reported by each patient at any time. Pain score is from 0 (no hurt) to 10 (hurts worst).
baseline, 1st, 2nd, 3rd and 7th day postoperatively
Highest VAS Pain Score during Exercise
Time Frame: baseline, 1st, 2nd, 3rd and 7th day postoperatively
Post-operative pain scores during Exercise, as assessed by Visual Analog Pain Scale (VAS) will be the primary outcome measured. Postoperative pain during Exerciset will be defined as the highest VAS pain score reported by each patient at any time. Pain score is from 0 (no hurt) to 10 (hurts worst).
baseline, 1st, 2nd, 3rd and 7th day postoperatively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2021

Primary Completion (Anticipated)

December 1, 2021

Study Completion (Anticipated)

February 1, 2022

Study Registration Dates

First Submitted

March 19, 2021

First Submitted That Met QC Criteria

July 14, 2021

First Posted (Actual)

July 16, 2021

Study Record Updates

Last Update Posted (Actual)

July 16, 2021

Last Update Submitted That Met QC Criteria

July 14, 2021

Last Verified

July 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CYYYMZK-E

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Frailty

Clinical Trials on ERAS exercise

Subscribe